The DuoBody technology platform offers a natural, unique and easy way to create bispecific antibodies with possible applications in different indications, including oncology, autoimmune disease, inflammation and infectious disease. Bispecific antibodies are the next step towards the development of effective treatments in the already successful field of antibody therapeutics. Genmab is seeking strategic partners interested in licensing the DuoBody platform or participating in the development of DuoBody platform-based therapeutics.
- Bispecific antibodies produced from the DuoBody platform can bind to two different epitopes either on the same or on different targets (also known as dual-targeting). By dual targeting, bispecific antibodies may increase specificity and engage multiple effector pathways. Dual targeting may also trigger specific recruitment of effector cells for target cell killing.
- Antibody sequences derived from any platform can be applied and combined for the generation of new bispecific antibodies, retaining the original antigen binding sites.
- The DuoBody generation process does not require reformatting, and is suitable for high throughput screening.
- Manufacturing of DuoBody is based on standard unit operations from a typical IgG1 monoclonal antibody platform process.
To read more about the DuoBody platform, visit DuoBody.com.
Back to top